Company: STAA
Filing Date: 2025-10-20
Form Type: DFAN14A
Source: 0001213900-25-100410
Chunk: 2

Company: STAAR SURGICAL CO
Filing Date: 2025-10-20
Form: DFAN14A
Chunk 2
---
8:30 a.m. (Pacific Time).

Neal C. Bradsher, Broadwood Founder and President, stated:

“It is clear the sale process that led to this
proposed transaction was deeply flawed and conflicted from the beginning. This proposed transaction comes at the wrong time, following
the wrong process, and at the wrong price. All three major shareholder advisory firms agree, in a rare example of unanimity among these
independent experts. So too do numerous shareholders. We continue to urge our fellow shareholders to vote ‘AGAINST’
the proposed transaction on the GREEN Proxy Card.”

To date, shareholders representing more than 34% of STAAR’s outstanding
common shares – including Yunqi Capital, Defender Capital, CalSTRS, former STAAR CEO David Bailey, and former STAAR executive Pascal
Aeschlimann – have communicated publicly that they oppose and intend to vote against the proposed acquisition of STAAR by Alcon.

Below is some commentary by these independent third-party shareholders
and proxy advisory firms.

The Wrong Time

<div align='center'>Exhibit 1-1</div>

The Wrong Process

<div align='center'>Exhibit 1-2</div>

| ● | “According to STAAR’s SEC filings, the Company’s named executive officers, stand to make an estimated $55 million                         
 in compensation from the proposed merger with Alcon. This includes approximately $24 million for CEO Stephen Farrell, a staggering amount 
 for just a few months of leadership since his appointment earlier this year. We believe these payouts reveal a significant conflict       
 of interest, providing blinding financial incentives for Mr. Farrell to push for a sale, both to the Board and shareholders, at a price   
 far below the Company’s intrinsic value, while bypassing a more robust and transparent process.” (Yunqi Capital, October                  
 6, 2025)                                                                                                                                  |

The Wrong Price

| ● | “STAAR’s own projections, shared with Alcon during merger discussions, anticipate growth from $260M in 2025 to                 
 nearly $500M by 2030. At this growth level, valuation multiples of 25x–40x would apply, implying values between $28 and        
 $44 per share—before any strategic premium … Alcon’s own M&A record suggests that premiums of 50–70%                           
 could reasonably be applied, lifting the valuation range into the $50+ zone—possibly as high as $60 in a competitive process.” 
 (Aeschlimann and